Mergers & AcquisitionsMedium•16 November 2026•
1 min read
Eli Lilly to Acquire Calytrix Bio in Deal Valued at $1.5 Billion
Key Facts
1Eli Lilly announced an agreement to acquire Calytrix Bio in a deal valued at up to $1.5 billion.
Eli Lilly announced an agreement to acquire Calytrix Bio in a deal valued at up to $1.5 billion. According to investing.com, the acquisition is a strategic move to expand the company's drug development pipeline through the integration of Calytrix Bio's assets.
Eli Lilly, trading under the ticker LLY, closed at $1443.5 on November 13, 2026. The acquisition aims to bolster the firm's pharmaceutical portfolio, following a session where the stock traded between a low of $1419.77 and a high of $1449.64 on November 13, 2026.